Opium Tincture Against Chronic Diarrhea - Healthy

Inclusion Criteria:

• Signed informed consent before any study specific procedures
• Able to read and understand Danish
• Male or female with an age of 20 years or more
• The researcher believes that the participant understands what the study entails, arecapable of following instructions, can attend when needed, and are expected tocomplete the study.
• The investigator will ensure that fertile female participants have a negativepregnancy test before each treatment visit and use contraception during the entity ofthe study.
• Opioid naïve (in this study "opioid naïve" is defined as a person who does not have ahistory of opioid use/addiction. If the opioids were used more than five years beforethe start of experiment as an analgesic to treat pain post-surgery etc., this personwill be considered opioid naïve. If the person has never used opioids to treat painbut has participated in pain studies where opioids were given more than a year beforethis experiment, this person will be considered opioid naïve)
• Healthy (assessed by a study-affiliated medical doctor)

Exclusion Criteria:

• Known allergy towards pharmaceutical compounds similar to Dropizol.
• Participation in other studies within 14 days of first visit (1 year if opioidsinvolved).
• Expected need of medical/surgical treatment during the study
• History of psychiatric illness (e.g. mental retardation, schizophrenia, affectivedisorders (depression), personality disorders or treatment with psychoactivemedications)
• History of substance abuse (e.g. alcohol, nicotine, tetrahydrocannabinol (THC),benzodiazepine, central stimulants and/or opioids)
• Family history of substance abuse
• Known increased intracranial pressure
• Known major stenosis of the intestines
• Planned MRI within the next 3 months
• Metal implants or pacemaker
• Known severe decreased renal function (defined as estimated glomerular filtration rate (eGFR) below 45)
• Known severe decreased hepatic function (defined as Child-Pugh class B or higher)
• Treatment with Monoamine oxidase (MAO) inhibitors during the entity of the study
• Known severe chronic obstructive pulmonary disease (COPD) or acute severe asthma (defined as forced expiratory volume in 1 second (FEV1) below 50 % or acute ongoingexacerbation)
• Known cor pulmonale
• Female participants that are lactating
• Medicine known to affect gastrointestinal motility must not be initiated during theentity of the study
• Use of any analgesic medication within 48 hours before start as well as for theduration of the study (urine drug test will be performed prior to treatment start).
• Intake of alcohol within 48 hours before start of study period as well as for theduration of the study.